Evidence map›Paper›PMID 40545966›Full record

ArticleThe American journal of surgical pathology2025

International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate.

Kenneth A Iczkowski, Angelo M De Marzo, Neeraj Agarwal, David M Berman, Alessia Cimadamore, Samson W Fine, Nancy Greenland, Francesca Khani, Massimo Loda, Tamara L Lotan and 12 more

Abstract readConsensus Statement
In one paragraph

Article in The American journal of surgical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kenneth A IczkowskiDepartment of Pathology and Laboratory Medicine, University of California-Davis Health, Sacramento.
Angelo M De MarzoDepartments of Pathology, Urology and Oncology, The Sidney Kimmel Comprehensive Cancer Center and The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD.
Neeraj AgarwalDepartment of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
David M BermanSurgery (Urology), Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, and Brown University Health, Brown University, Providence, RI.
Alessia CimadamoreDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
Samson W FineDepartment of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center.
Nancy GreenlandDepartment of Pathology, University of California-San Francisco, San Francisco, CA.
Francesca KhaniPathology and Laboratory Medicine at Weill Cornell Medicine, New York, NY.
Massimo LodaPathology and Laboratory Medicine at Weill Cornell Medicine, New York, NY.
Tamara L LotanDepartment of Pathology, Johns Hopkins University, Baltimore, MD.
Murali VarmaCellular Pathology, University Hospital of Wales, Cardiff, UK.
Arul ChinnaiyanDepartment of Pathology, University of Michigan, Ann Arbor, MI.
Gianluca GiannariniDepartment of Urology, Santa Maria della Misericordia University Hospital, Udine, Italy.
Jiaoti HuangDepartment of Pathology, Duke University, Durham, NC.
Rodolfo MontironiInstitute of Pathological Anatomy, Università Politecnica delle Marche.
George J NettoDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
Adeboye O OsunkoyaDepartments of Pathology and Urology, Emory University School of Medicine, Atlanta, GA.
Timothy RatliffPurdue University College of Veterinary Medicine, West Lafayette, IN.
Glen KristiansenInstitute of Pathology, Bonn, Germany.
Liang ChengDepartments of Pathology and Laboratory Medicine.
Geert J L H van LeendersDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Members of the ISUP GU Cancer Precursor Consensus Panel

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Working Group 1 at ISUP's Cancer Precursors meeting (September 2024) evaluated 5 putative precursors of invasive prostate cancer: high-grade prostatic intraepithelial neoplasia (HGPIN), intraductal carcinoma (IDC), atypical intraductal proliferation (AIP), atypical adenomatous hyperplasia (AAH)/adenosis, and proliferative inflammatory atrophy (PIA). Objectives were to compile recent evidence, interrogate current practices, and vote on recommendations, with 67% approval defined as consensus. Consensus was reached against the reporting of the low-grade form of PIN. HGPIN need not be reported when concomitant cancer or atypical small acinar proliferation suspicious for cancer exists adjacent to it, for biopsy or prostatectomy specimens. Finally, while the clinical significance of unifocal HGPIN in biopsies remains uncertain, there is stronger evidence for multifocal isolated HGPIN as a predictor of subsequent cancer detection. By consensus, multifocal HGPIN should continue being reported. Slight refinement was achieved regarding IDC criteria. The consensus opinion was that a dense cribriform to solid proliferation need not demonstrate marked nuclear atypia/ pleomorphism to qualify as IDC. The inverse scenario of marked atypia without dense cribriform/solid proliferation fell just short (65%) of consensus for IDC. Redesignating cribriform HGPIN as AIP achieved consensus. AIP found alone or with grade group 1 cancer warrants an explanatory comment. However, agreement was not attained to report AIP in the presence of invasive cancer, in either needle biopsy or prostatectomy. Finally, the optional reporting of PIA or AAH/adenosis in biopsies as pertinent negatives both fell short of consensus. This guidance should help pathologists standardize reporting, staying focused on the clinically actionable aspects of these lesions.

Indexed as

Precancerous ConditionsProstateProstatic Intraepithelial NeoplasiaProstatic NeoplasmsHumansMaleNeoplasm Gradingatypical intraductal proliferationconsensus conferenceintraductal carcinomaprecursor lesionprostateprostatic intraepithelial neoplasia

Identifiers

PMID40545966
PMCPMC12754735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.